Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial

Gary Raskob Nick van Es Annelise Segers Pantep Angchaisuksiri Doyeun Oh Zoltán Boda 1 Roger Lyons Karina Meijer 2 Ivan Gudz Jeffrey Weitz 3 George Zhang Hans Lanz Michele Mercuri Harry Büller Dominique Mottier 4, 5
1 DEBRECEN - Dpt Medicine - Department of Medicine
2 Haematology
3 McMaster University [Hamilton, Ontario]
4 GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale
5 CIC Brest
Document type :
Journal articles
Complete list of metadatas
https://hal.univ-brest.fr/hal-02043621
Contributor : Ghislaine Calvez <>
Submitted on : Thursday, February 21, 2019 - 10:23:04 AM
Last modification on : Friday, February 22, 2019 - 1:30:20 AM

Identifiers

  • HAL Id : hal-02043621, version 1

Collections

UNIV-BREST | GETBO | IBSAM

Citation

Gary Raskob, Nick van Es, Annelise Segers, Pantep Angchaisuksiri, Doyeun Oh, et al.. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. The Lancet Haematology, Elsevier, 2016, 3 (8), pp.e379-e387. ⟨hal-02043621⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

41

Contact

Informations

CCSD